Stereotaxis, Inc. 10-Q Summary: Quarter Ended September 30, 2010
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended September 30, 2010, for Stereotaxis, Inc., a Delaware corporation. The company designs, manufactures, and markets the Niobe Remote Magnetic Navigation System and the Odyssey portfolio of products for interventional cardiology. The filing is an unaudited quarterly report.
Key Financial Metrics
| Metric | Three Months Ended Sep 30, 2010 | Nine Months Ended Sep 30, 2010 |
|---|---|---|
| Total Revenue | $13.87 million | $39.51 million |
| Gross Margin | $10.02 million (72%) | $27.81 million (70%) |
| Operating Loss | $(3.59) million | $(15.54) million |
| Net Loss | $(5.14) million | $(17.43) million |
| Cash and Equivalents | $21.79 million (as of Sep 30, 2010) | |
| Working Capital | $(6.22) million deficit | |
| Total Debt | $26.52 million ($20.97M current; $5.56M long-term) | |
| Net Cash Used in Operating Activities | $(14.08) million (9 months) |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 4% quarter-over-quarter (QoQ) and 7% year-over-year (YoY) for the nine-month period. This was driven by a 24% QoQ increase in disposables, service, and accessories revenue, offset by a 6% QoQ decline in systems revenue.
- Margin Expansion: Gross margin improved to 72% (QoQ) and 70% (YoY 9-month) due to a favorable shift in revenue mix toward higher-margin recurring services and disposables.
- Expense Trends: Sales and marketing expenses increased 16% QoQ due to additional headcount. Research and development expenses decreased 13% QoQ due to reduced consulting costs.
- Liquidity Shift: The company moved from a working capital surplus of $22.9 million at year-end 2009 to a deficit of $6.2 million. This was primarily caused by the reclassification of $10 million of debt to current maturities and the net loss for the period.
- Debt Structure: Total debt increased to $26.5 million. The revolving line of credit balance rose to $17.0 million, and the company has minimal remaining borrowing capacity ($0.2 million) under current collateral limits.
Outlook, Risks, and Management Commentary
- Revenue Recognition Changes: Beginning in Q2 2010, revenue for Odyssey Vision Quad systems was recognized upon delivery rather than installation, adding $1.2 million in revenue and $0.6 million in gross margin for that quarter.
- Liquidity Outlook: Management expects negative cash flow from operations for the full year 2010. While current cash and borrowing facilities are expected to fund operations for the next 12 months, the primary credit facility expires March 31, 2011. The company is in discussions to renew and potentially expand this facility.
- Operational Headwinds: Revenue growth in the second half of 2010 is being impacted by installation delays, though management does not expect this to significantly impact liquidity in the near term.
- Subsequent Event: In November 2010, the company was awarded $1.5 million in grants under the Qualifying Therapeutic Discovery Project Program, with $1.1 million expected in Q4 2010.
- Risks: Key risks include the need for additional financing if credit facilities are not renewed, foreign exchange exposure (15% of revenue in foreign currencies), and the potential for dilution if equity financing is required.
Investor Verification Checklist
- Verify the status of negotiations to renew the $30 million revolving credit facility expiring March 31, 2011.
- Monitor the impact of installation delays on Q4 2010 revenue recognition and cash collections.
- Review the terms of the Biosense Webster agreement, specifically the "Accelerating Recoupment Event" triggers that could accelerate debt repayment.
- Assess the sustainability of the shift in revenue mix toward disposables and services versus capital equipment sales.
- Confirm the receipt and timing of the $1.5 million grant award mentioned in subsequent events.